Invasive Dental Procedure in Patient on Enhertu: Contraindications and Clearance
Enhertu (trastuzumab deruxtecan) is NOT a bone-modifying agent and does NOT carry the same risk of medication-related osteonecrosis of the jaw (MRONJ) as bisphosphonates or denosumab—therefore, invasive dental procedures with jaw bone manipulation can proceed with standard precautions after hematology/oncology clearance addresses systemic factors only.
Key Distinction: Enhertu vs. Bone-Modifying Agents
The critical issue here is drug classification. The MASCC/ISOO/ASCO guidelines 1 specifically define MRONJ risk in the context of:
- Bone-modifying agents (BMAs): bisphosphonates and denosumab
- Angiogenic inhibitors: bevacizumab and similar agents
Enhertu is an antibody-drug conjugate (ADC) targeting HER2 with a topoisomerase I inhibitor payload 2. It is neither a BMA nor a traditional angiogenic inhibitor. The FDA label 2 does not list MRONJ or dental complications as warnings or precautions.
What Heme/Onc Clearance Should Address
The clearance should focus on systemic safety factors from Enhertu's known toxicity profile:
1. Hematologic Parameters (Most Critical)
From the FDA label 2, common hematologic toxicities include:
- Neutropenia: 70% all grades, 18% grade 3-4
- Thrombocytopenia: 52% all grades, 7% grade 3-4
- Anemia: 64% all grades, 7% grade 3-4
Acceptable pre-procedure thresholds:
- ANC >1,500/μL (ideally >2,000/μL)
- Platelets >50,000/μL for minor procedures, >75,000/μL for extensive bone manipulation
- Hemoglobin >8 g/dL
2. Infection Risk Assessment
- Check for active infections (Enhertu increases respiratory infection risk 2)
- Ensure no febrile neutropenia (0.8% incidence 2)
- Consider prophylactic antibiotics if ANC 1,000-1,500/μL
3. Timing Relative to Enhertu Dosing
Enhertu is dosed every 3 weeks 2. Optimal timing:
- Schedule dental procedure 10-14 days after last Enhertu dose (nadir period passed, before next dose)
- Allow 7-10 days healing before next Enhertu cycle if possible
4. Interstitial Lung Disease (ILD) Status
ILD occurs in 11% of patients 2. If patient has active or recent ILD:
- Defer elective procedures
- Coordinate with pulmonology if urgent procedure needed
No MRONJ-Specific Precautions Required
Unlike patients on denosumab 3 or bisphosphonates 1, you do NOT need:
- Extended drug holidays (no evidence this helps with Enhertu)
- MRONJ staging protocols
- Specialized minimally invasive techniques beyond standard surgical principles
- Prolonged healing observation periods specific to osteonecrosis risk
Practical Algorithm
Step 1: Verify patient is NOT on concurrent BMAs (bisphosphonates/denosumab) or high-dose steroids
- If yes → follow MRONJ guidelines 1
- If no → proceed to Step 2
Step 2: Obtain CBC within 7 days of procedure
- ANC >1,500, platelets >50,000, Hgb >8 → proceed
- Below thresholds → delay until recovery or transfuse as needed
Step 3: Confirm no active ILD or systemic infection
- If present → defer elective procedures
Step 4: Time procedure optimally (10-14 days post-Enhertu dose)
Step 5: Use standard surgical technique with:
- Perioperative antibiotics (standard prophylaxis, not extended courses)
- Meticulous hemostasis
- Primary closure when possible
- Standard post-op care
Common Pitfalls to Avoid
Conflating Enhertu with bevacizumab: While both are cancer biologics, bevacizumab (anti-VEGF) has documented MRONJ risk 1. Enhertu does not share this mechanism.
Unnecessary drug holidays: The MASCC guidelines 1 note insufficient evidence even for BMA discontinuation before dental surgery. For Enhertu (not a BMA), there is zero evidence supporting discontinuation.
Over-restriction of necessary dental care: Delaying medically necessary extractions in cancer patients can worsen outcomes 4. The study showed dental treatment before oncologic procedures has acceptable safety (1.6% complication rate 4).
Ignoring concurrent medications: Check for actual BMAs, high-dose steroids, or other immunosuppressants that DO increase MRONJ risk 1, 5.
Documentation for Clearance
Heme/onc should document:
- Current CBC values and acceptability
- Timing recommendation relative to Enhertu cycle
- ILD status
- Any concurrent medications affecting bone/wound healing
- Explicit statement: "Patient on Enhertu (not a BMA); standard dental surgical precautions apply"
The bottom line: Enhertu itself is not a contraindication to invasive dental procedures. Clearance should address systemic factors (counts, infection, timing) but does not require MRONJ-specific protocols.